BioMarin prices its hemophilia gene therapy at about US$1.5M following European approval by Editor | Aug 26, 2022 | Government, Regulatory & Policy News, LATEST NEWS, Pharmaceuticals & Manufacturing, WORLD NEWS | 0 USA- California-based biotechnology company BioMarin has announced that European regulators have... Read More